ATE353920T1 - Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie - Google Patents

Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie

Info

Publication number: ATE353920T1
Authority: AT; Austria
Prior art keywords: cam; monoclonal antibodies; antibodies against; cancer therapy; human monoclonal
Prior art date: 1999-12-27

Application number

AT04102692T

Other languages

English (en)

Inventor

Ton Dr Logtenberg

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-27

Filing date

2000-12-21

Publication date

2007-03-15

2000-12-21 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE353920T1 publication Critical patent/ATE353920T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT04102692T 1999-12-27 2000-12-21 Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie ATE353920T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99204561		1999-12-27

Publications (1)

Publication Number	Publication Date
ATE353920T1 true ATE353920T1 (de)	2007-03-15

Family

ID=8241110

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT00991344T ATE366419T1 (de)	1999-12-27	2000-12-21	Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken
AT02077516T ATE386747T1 (de)	1999-12-27	2000-12-21	Antikörper gegen ep-cam
AT04102692T ATE353920T1 (de)	1999-12-27	2000-12-21	Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AT00991344T ATE366419T1 (de)	1999-12-27	2000-12-21	Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken
AT02077516T ATE386747T1 (de)	1999-12-27	2000-12-21	Antikörper gegen ep-cam

Country Status (11)

Country	Link
US (2)	US20030096225A1 (de)
EP (3)	EP1273918B1 (de)
JP (1)	JP2003518391A (de)
AT (3)	ATE366419T1 (de)
AU (1)	AU783148B2 (de)
CA (1)	CA2396029A1 (de)
DE (3)	DE60038132T2 (de)
DK (1)	DK1479696T3 (de)
ES (1)	ES2282797T3 (de)
NZ (2)	NZ520074A (de)
WO (1)	WO2001048485A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
MXPA04010222A (es) *	2002-04-17	2005-03-07	Roberto Crea	Dopacion en mutagenesis en ruta.
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
EP2314629B2 (de)	2002-07-18	2022-11-16	Merus N.V.	Rekombinante Herstellung von Mischungen aus Aantikörpern
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP2374465A1 (de) *	2003-09-08	2011-10-12	E. I. du Pont de Nemours and Company	Pflegespülung auf Peptidbasis und Färbemittel für Haar, Haut und Nägel
AU2005205412B2 (en)	2004-01-20	2011-08-11	Merus N.V.	Mixtures of binding proteins
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US9079942B2 (en)	2009-02-09	2015-07-14	Epitomics, Inc.	CDR-anchored amplification method
GB0909904D0 (en)	2009-06-09	2009-07-22	Affitech As	Product
US8293483B2 (en)	2009-09-11	2012-10-23	Epitomics, Inc.	Method for identifying lineage-related antibodies
CN110763842A (zh)	2011-06-29	2020-02-07	中央研究院	使用表面涂层对生物物质的捕获、纯化和释放
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
CN104168916B (zh) *	2012-03-02	2017-07-04	中央研究院	抗上皮细胞黏着分子(EpCAM)抗体及其使用方法
DK2838918T3 (da)	2012-04-20	2019-08-12	Merus Nv	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
CN106662514A (zh)	2014-04-01	2017-05-10	中央研究院	用于癌症诊断及预后的方法和系统
CN105381824B (zh)	2014-08-26	2019-04-23	中央研究院	收集器架构布局设计
US10107726B2 (en)	2016-03-16	2018-10-23	Cellmax, Ltd.	Collection of suspended cells using a transferable membrane
US20210246519A1 (en) *	2018-05-04	2021-08-12	The Regents Of The University Of California	Spiked primers for enrichment of pathogen nucleic acids among background of nucleic acids
CN115397867A (zh) *	2020-04-13	2022-11-25	艾弗依姆恩治疗公司	Epcam抗体与car-t细胞
CN116600819A (zh) *	2020-12-09	2023-08-15	艾弗依姆恩治疗公司	靶向epcam和icam-1的双嵌合抗原受体
WO2023174521A1 (en)	2022-03-15	2023-09-21	Genmab A/S	Binding agents binding to epcam and cd137
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5605793A (en) *	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US6265150B1 (en) *	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
JP2001512560A (ja) *	1996-10-08	2001-08-21	ユー―ビスイスベスローテンフェンノートシャップ	標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
US6787638B1 (en) *	1998-12-02	2004-09-07	Applied Molecular Evolution, Inc.	Tumor specific human monoclonal antibodies and methods of use

2000
- 2000-12-21 CA CA002396029A patent/CA2396029A1/en not_active Abandoned
- 2000-12-21 AU AU32447/01A patent/AU783148B2/en not_active Ceased
- 2000-12-21 AT AT00991344T patent/ATE366419T1/de not_active IP Right Cessation
- 2000-12-21 EP EP02077516A patent/EP1273918B1/de not_active Expired - Lifetime
- 2000-12-21 NZ NZ520074A patent/NZ520074A/en unknown
- 2000-12-21 EP EP00991344A patent/EP1242823B1/de not_active Expired - Lifetime
- 2000-12-21 AT AT02077516T patent/ATE386747T1/de not_active IP Right Cessation
- 2000-12-21 DK DK04102692T patent/DK1479696T3/da active
- 2000-12-21 ES ES04102692T patent/ES2282797T3/es not_active Expired - Lifetime
- 2000-12-21 WO PCT/NL2000/000941 patent/WO2001048485A2/en not_active Ceased
- 2000-12-21 DE DE60038132T patent/DE60038132T2/de not_active Expired - Lifetime
- 2000-12-21 DE DE60035434T patent/DE60035434T2/de not_active Expired - Lifetime
- 2000-12-21 JP JP2001549082A patent/JP2003518391A/ja not_active Withdrawn
- 2000-12-21 AT AT04102692T patent/ATE353920T1/de active
- 2000-12-21 DE DE60033455T patent/DE60033455T2/de not_active Expired - Lifetime
- 2000-12-21 NZ NZ531590A patent/NZ531590A/en unknown
- 2000-12-21 EP EP04102692A patent/EP1479696B1/de not_active Expired - Lifetime
2002
- 2002-06-27 US US10/184,508 patent/US20030096225A1/en not_active Abandoned
- 2002-06-28 US US10/186,186 patent/US7777010B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1273918B1 (de)	2008-02-20
AU3244701A (en)	2001-07-09
DE60038132D1 (de)	2008-04-03
JP2003518391A (ja)	2003-06-10
DK1479696T3 (da)	2007-05-07
DE60033455D1 (de)	2007-03-29
CA2396029A1 (en)	2001-07-05
EP1242823A2 (de)	2002-09-25
EP1273918A2 (de)	2003-01-08
EP1479696A1 (de)	2004-11-24
AU783148B2 (en)	2005-09-29
EP1242823B1 (de)	2007-07-04
NZ531590A (en)	2006-01-27
ATE366419T1 (de)	2007-07-15
WO2001048485A3 (en)	2002-01-31
US20030096225A1 (en)	2003-05-22
EP1479696B1 (de)	2007-02-14
EP1273918A3 (de)	2003-05-02
US7777010B2 (en)	2010-08-17
DE60035434D1 (de)	2007-08-16
DE60035434T2 (de)	2008-05-15
DE60033455T2 (de)	2007-11-29
WO2001048485A9 (en)	2002-09-06
ES2282797T3 (es)	2007-10-16
WO2001048485A2 (en)	2001-07-05
US20030096226A1 (en)	2003-05-22
NZ520074A (en)	2004-04-30
ATE386747T1 (de)	2008-03-15
DE60038132T2 (de)	2009-04-02

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1479696

Country of ref document: EP

Publication	Publication Date	Title
DE60033455D1 (de)	2007-03-29	Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
CY1120070T1 (el)	2018-12-12	Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE69724428D1 (de)	2003-10-02	Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
DE69433406T2 (de)	2004-10-07	Antikörper gegen cd40
CY1119291T1 (el)	2018-02-14	Πολυσθενη αντισωματα και χρησεις για αυτα
DE69941598D1 (de)	2009-12-10	Anti-ccr2 antikörper sowie deren verwendung
EP1071458A4 (de)	2005-02-16	Humanisierter antikörper und dessen verwendungen
ATE483733T1 (de)	2010-10-15	Hochaffine humane antikörper gegen tumorantigene
DE60018761D1 (de)	2005-04-21	Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
DE60130538D1 (de)	2007-10-31	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE122012000001I1 (de)	2012-03-15	Humane antikorper gegen CTLA-4 und deren verwendungen.
ID28088A (id)	2001-05-03	Antibodi untuk cd23, turunan-turunannya dan penggunannya untuk terapi
DE69734887D1 (de)	2006-01-19	Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
IN2014DN05011A (de)	2015-07-10
DK2316852T3 (da)	2014-06-16	Stabiliserede enkeltdomæne-antistoffer
SI1572087T1 (sl)	2008-10-31	Protitelesa proti antigenu tmeff2 raka in njihovauporaba
DE60217698D1 (de)	2007-03-08	Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
ATE366746T1 (de)	2007-08-15	Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
PT840620E (pt)	2002-04-29	Antagonistas de il-8 para o tratamento de asma
DE69938725D1 (de)	2008-06-26	Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE69504959D1 (de)	1998-10-29	Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE221663T1 (de)	2002-08-15	Prionbindende proteine und deren verwendungen
TR200103432T2 (tr)	2002-10-21	Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE362490T1 (de)	2007-06-15	Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE69838646D1 (de)	2007-12-13	Isolierte decapeptide, die an hla moleküle binden, sowie deren verwendung